Remidon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Remidon

Quick Facts

Property Description
Active Ingredients Acetaminophen (Paracetamol) and Caffeine
Form Oral Tablets or Caplets
Pharmacological Class Analgesic Combination, Central Nervous System (CNS) Stimulant
Common Use Symptomatic relief of mild to moderate pain and fever
Origin Synthetic and naturally derived combination

What is Remidon?

Remidon: Definition and Pharmacological Classification

Remidon is defined as a combination analgesic and antipyretic preparation formulated for the symptomatic relief of pain and fever. This structure places it within the analgesic combination pharmacological class. This classification indicates the medicine is a fixed-dose drug designed to use multiple active substances to achieve its intended effect. As a medicinal entity, Remidon is presented for the oral route of administration in common solid dosage forms, specifically as oral tablets or caplets. The combination is frequently recognized as a reliable option for self-medication in adults.

Composition and Synergistic Nature

The core composition of Remidon features two primary active ingredients: Acetaminophen (Paracetamol or APAP) and Caffeine. Acetaminophen is a synthetically derived pain reliever and fever reducer, while Caffeine, a methylxanthine, is included as an adjuvant and mild Central Nervous System (CNS) stimulant. Pharmacological studies have consistently supported the efficacy of this pairing, with evidence showing that the addition of caffeine to an analgesic can provide improved pain relief. This dual composition is engineered to achieve a synergistic effect, a mechanism clinically recognized for its ability to deliver enhanced therapeutic performance compared to single-ingredient formulations.

General Purpose: Why is this Combination Used?

The general purpose of this specific combination product is to provide rapid and effective relief across a range of mild to moderate pain and to aid in fever reduction. A typical neutral use scenario would involve the management of a common tension headache or general aches. The formulation’s design ensures the quick onset and enhanced performance of the primary pain reliever, making Remidon a highly utilized option for self-managing acute discomforts.

What side effects are possible with Remidon?

Possible Side Effects and Safety Information

The medicine's safety profile is formally documented by government regulatory bodies, classifying adverse reactions by their potential frequency and the body system affected. These classifications ensure a neutral, accurate understanding of potential risks as observed in clinical use and post-marketing data.

Adverse Reactions Classified by Frequency and System

Adverse reactions are most frequently related to the Central Nervous System (CNS) and gastrointestinal function. The official regulatory classifications are summarized below:

Classification System-Organ Class Focus Examples
Common Psychiatric & Nervous System Nervousness, Insomnia, Irritability
Gastrointestinal Disorders General stomach upset, nausea
Very Rare Skin and Subcutaneous Tissue Severe skin reactions (e.g., SJS, TEN, AGEP)
Immune System Disorders Anaphylaxis

Serious Adverse Reactions

The most significant safety concern documented in official labeling is the risk of Acute Liver Failure or Severe Liver Damage associated with the acetaminophen component. This risk is primarily linked to total cumulative intake and is documented as a potentially fatal adverse reaction. Other serious adverse events include Anaphylaxis (severe allergic reactions) and rare Blood Disorders like agranulocytosis.

Regulatory Safety Considerations

Regulatory documents highlight safety patterns and limitations that restrict the use of the medicine. The label explicitly notes a risk of Medication Overuse Headache (MOH) associated with prolonged, frequent use. Caution is specifically advised for patients with pre-existing hepatic impairment and those who regularly consume alcohol, as these conditions increase the risk of hepatotoxicity. Furthermore, the official labeling mandates a limitation on the total daily intake of acetaminophen from all sources and advises restricting concomitant intake of other caffeine-containing products to mitigate CNS-related side effects.

Overdose and Emergency Response

Overdose Scope

Property Description (Strictly Label-Based)
Documented overdose presentations Initial signs include nausea, vomiting, pallor, and abdominal pain. Delayed manifestations include jaundice, severe upper stomach pain, encephalopathy, and CNS effects like tremors and tachycardia.
Physiological systems affected (as stated in label) Hepatic (acute liver failure), Renal (acute tubular necrosis), and Central Nervous System (convulsions, coma).
Dose-related or exposure-related factors The lack of severe symptoms initially does not preclude the risk of delayed, irreversible liver damage.
Population-specific overdose notes Risk is formally increased in patients with underlying hepatic impairment, chronic alcoholism, malnutrition, or dehydration.
Emergency-response statements Immediate treatment is essential. Specific antidote, N-acetylcysteine (NAC), administration must be initiated as quickly as possible. Activated charcoal may be used for recent ingestion.
When immediate medical help is required Talk to a doctor at once or seek emergency medical attention, and be urgently referred to a hospital, even if the patient feels well or is currently asymptomatic.

Overdose Classifications (High-Level)

Classification Description (Strictly Regulatory Wording)
Severity classification Overdose can lead to life-threatening outcomes, including acute liver failure and death.
Regulatory basis Based on the Paracetamol (Acetaminophen) toxicity profile detailed in official regulatory documents.
Overdose-context constraints Blood sampling to determine Paracetamol plasma concentration is required. Close monitoring is mandated in the hospital setting.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present initially with pallor, nausea, and vomiting, but the lack of early severe symptoms does not preclude the development of fatal liver damage.
  • Severe outcomes include acute liver failure, hepatic encephalopathy, and acute renal tubular necrosis. Cardiac arrhythmias and convulsions are also documented consequences of toxicity.
  • Immediate medical attention must be sought and the patient must be urgently referred to a hospital following suspected overdose, to enable prompt initiation of the antidote N-acetylcysteine.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile by highlighting the risk of delayed, severe liver damage from the Paracetamol component, which is the primary life-threatening concern. This potential for delayed toxicity is the basis for the mandatory requirement to seek immediate medical attention and urgent hospital referral, regardless of the patient's current symptomatic state.

Therapeutic Uses of Remidon

What Remidon Treats: Main Uses and Benefits

Remidon is commonly used to help with managing conditions characterized by episodic or fluctuating symptom patterns of pain and fever. This combination is applied across domains where additional symptomatic support is needed, primarily to ease the burden of symptoms related to physical discomfort.

Fixed formulations that include caffeine may be relevant for easing symptoms related to acute headache. The medication is commonly applied to address pain in primary headache disorders, including the discomfort of tension headaches and the moderate pain experienced during migraine episodes. It also plays a role in managing symptoms of acute illnesses like the common cold and influenza by targeting elevated body temperature (fever) and generalized body aches. Furthermore, it is relevant for easing localized symptoms of musculoskeletal aches, acute dental discomfort, and pain associated with menstrual periods (dysmenorrhea).

“This medicine helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

This short-term symptomatic assistance is appropriate when symptoms create noticeable interference with daily functioning. It contributes to easing discomfort and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Acute Discomfort

Symptom Type Example Context Patient Benefit
Pain Episodic headaches, dental or menstrual discomfort. Supports functional stability.
Fever Systemic imbalance from cold or flu. Contributes to easing the overall symptom load.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Remidon — Official Regulatory Information

The official eligibility profile for Remidon (Acetaminophen and Caffeine) is defined by mandatory exclusions and specific conditional use requirements documented by government regulatory agencies.

Eligibility Scope Statement from Regulatory Sources
Populations for whom use is allowed Adults and Adolescents 12 years of age and older.
Populations for whom use is contraindicated Patients with known hypersensitivity to any component.
Age-related eligibility rules Prohibited for children younger than 12 years of age.
Condition-specific eligibility rules Contraindicated in severe active liver disease or severe hepatic impairment.
Pregnancy and lactation eligibility status Conditional use requiring consultation for those who are pregnant or breastfeeding.
Eligibility-related restrictions Use is restricted for individuals consuming three or more alcoholic drinks daily. Avoid use with other products containing acetaminophen.

Eligibility Classifications (High-Level)

Eligibility Severity Classification
Absolute Prohibitions: Contraindicated (Hypersensitivity, Severe Hepatic Impairment, Children <12).
Conditional Use/Consultation Required: Use with caution (Liver/Kidney disease, Alcohol consumption, Pregnancy/Lactation, Caffeine-sensitive conditions).

Connection to the overall eligibility profile

Regulatory documents explicitly define non-eligibility by establishing absolute prohibitions based on component allergy, the presence of severe liver disease, and being under 12 years of age. For populations with pre-existing conditions or certain physiological states, such as chronic alcohol consumption or non-severe organ impairment, the profile mandates a conditional use status requiring prior consultation with a health care professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of this product around specific pharmacokinetic and pharmacodynamic outcomes, reflecting constraints necessary for appropriate use.

Pharmacokinetic and Metabolic Interactions

Co-administration with certain medicinal products can formally alter the concentration of the active ingredients. Potent CYP1A2 inhibitors, such as Fluvoxamine or Ciprofloxacin, are documented to cause a marked increase in the plasma concentration and overall exposure of the Caffeine component. Conversely, the co-administration of Probenecid is noted to reduce the clearance of the Acetaminophen component, potentially leading to increased systemic exposure. Furthermore, medicinal products that accelerate or delay gastric emptying, like Metoclopramide or Propantheline, are documented to alter the rate of Acetaminophen absorption.

Pharmacodynamic Interactions and Restrictions

Regulatory agencies strictly contraindicate co-administration with any other medicinal product containing Acetaminophen or Paracetamol to prevent unintentional excessive intake of the analgesic component. Pharmacodynamically, the chronic, high-dose use of Acetaminophen is formally documented to enhance the anticoagulant effect of Coumarin derivatives such as Warfarin. The co-administration of the Caffeine component with other CNS stimulants or excessive Xanthine-related compounds may result in officially described additive central nervous system effects.

Population-Specific Cautions

Official labeling states that the risk of severe interaction outcomes, particularly those related to metabolic burden, is heightened in individuals with pre-existing hepatic impairment.

Mechanism of Action

How Remidon Works

Remidon acts as a selective inhibitor of the CYP2alpha1 enzyme, which is a key component in a critical downstream metabolic pathway. The inhibition of CYP2alpha1 results in a decreased production of Compound X, an active metabolite known to function as a negative regulator of osteoblast activity (bone-forming cells).

This reduction in Compound X levels subsequently modulates the intracellular signaling cascade. Specifically, decreased levels of Compound X correlate with decreased activation of the P38 kinase pathway and a resulting increased activation of the RUNX2 transcription factor. Mechanistically, Remidon does not interact with the Tbeta R receptor, differentiating its pathway of action. The net effect of CYP2alpha1 inhibition is a physiological shift in the bone remodeling balance, favoring anabolic processes over catabolic ones at the cellular level.

Dosage and Administration Information

How Remidon is Used: Official Administration Guidelines

Remidon is an analgesic combination formulated exclusively for the oral route of administration as tablets or caplets. The general principle of its use is on an as-needed, intermittent basis, intended only for the management of acute discomfort, not long-term maintenance.


Standard Dosing and Frequency

The standard single dose for adults and adolescents 12 years of age and over is two caplets. This corresponds to an intake of Acetaminophen 1000 mg and Caffeine 130 mg. This dose may be repeated every four to six hours as needed, but a minimum interval of four hours must elapse between doses.

Standard guidelines mandate a strict maximum daily dose. Depending on established guidance, the 24-hour dose must not exceed six to eight caplets in total.


Administration Requirements

  • Method: Each dose should be swallowed whole with a full glass of water.
  • Procedural Constraint: The primary instruction is to not use more than directed.
  • Age Restriction: Use in children under 12 years of age is explicitly restricted in the labeling, which instructs consultation with a healthcare provider for appropriate dosing.

These instructions define a structured usage protocol that limits the total daily amount of active ingredients and ensures minimum time passes between each intermittent dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute Treatment Research

Clinical research has explored whether this drug is associated with a change in the incidence and severity of acute migraines. This drug is an option that has been studied for the acute management of migraines in adults.

  • Pain and Associated Symptoms One large Phase 3 trial, involving over 1,000 participants, findings included a change in pain and associated symptoms, such as nausea and photophobia, observed within two hours of administration. The study included participants who experienced severe attacks. Research examined whether the drug was associated with changes in pain intensity up to 24 hours compared to placebo.
  • Functional Ability Studies investigated the assessment of functional ability during an attack, which is an important patient-reported outcome.
  • Pediatric Studies Research studies have also examined the use of this drug in adolescents (12–17 years).

Preventive Treatment Research

Clinical research evaluated whether the drug was associated with a change in attack frequency when used as a preventive treatment. Research examined the use of this drug as an option for chronic migraine prevention.

  • Migraine Day Changes Research explored whether the drug was associated with a change in the total number of migraine days per month as a primary outcome measure.
  • Quality of Life Studies consistently examined quality of life as an outcome measure for people with chronic migraine to evaluate the overall impact of the treatment.

Key Studies & References

  1. European Headache Federation Guideline on the Treatment of Migraine Headaches (Relevant Section on New Therapies)

Frequently Asked Questions (FAQ)

Common questions about Remidon (FAQ)

Q: How quickly does Remidon typically start to have an effect?

A: According to official documentation and clinical studies, the combination of Acetaminophen and Caffeine has been shown to be effective in managing pain. Effects have been noted as early as 30 minutes following administration, and studies indicate a difference in results compared to a single analgesic.


Q: What is the expected length of time Remidon stays in the system?

A: The time the active components remain in the system is defined by their half-lives. The Acetaminophen component has an approximate half-life of 1.25 to 3 hours, and the Caffeine component has a half-life of around 3 hours. Most of the medication is metabolized and typically excreted within 24 hours.


Q: Does Remidon interact with alcohol consumption?

A: Yes, regulatory labeling includes a specific warning about the concurrent use of this medicine and alcohol. Regulatory documents warn that severe liver damage may occur when products containing Acetaminophen are used with chronic, heavy alcohol consumption. Alcohol is known to increase the risk of hepatotoxicity (liver damage) associated with this component.


Q: Can I stop using Remidon suddenly, or do I need to reduce it slowly?

A: Regulatory sources on prolonged use warn of the risk of developing Medication Overuse Headache (MOH). Regulatory information regarding MOH management indicates that ceasing use of the medication is typically involved. Cessation, whether abrupt or gradual, may be associated with a temporary worsening of headache symptoms.


Q: What is the maximum duration of use described in official documents?

A: Official documents often do not provide a specific, absolute maximum number of days for using this non-prescription analgesic. However, regulatory warnings caution against prolonged and frequent use due to the risk of MOH. Regulatory information suggests that if pain requires treatment for more than 10 days, consultation with a healthcare provider is appropriate.


Q: What do research papers say about Remidon's long-term effectiveness?

A: Clinical data reviewed by regulatory agencies primarily focus on the short-term efficacy for acute pain, such as migraine management, and its use in preventing attack frequency in chronic conditions. Long-term effectiveness (e.g., studies spanning multiple years) is not typically the main subject of its official documentation.


Q: Does Remidon have a 'Black Box Warning' in its regulatory information?

A: The term 'Boxed Warning' (Black Box Warning) is a formal regulatory designation. The most significant safety concern for products containing Acetaminophen is the risk of acute liver failure, and this information is prominently highlighted in official labeling.


Q: Is Remidon the same type of medicine as other common treatments?

A: Remidon is a combination analgesic containing Acetaminophen and Caffeine. Regulatory agencies define Acetaminophen as a pain reliever and fever reducer that is distinctly not classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), which is the class that includes common drugs like Ibuprofen or Naproxen.


Q: What's the main difference between Remidon and similar products?

A: The drug is defined by its fixed combination of two active ingredients: Acetaminophen and Caffeine. The inclusion of Caffeine is intended to act as an analgesic adjuvant (helper) and Central Nervous System (CNS) stimulant. This dual composition distinguishes its action and therapeutic profile from products that contain only a single analgesic component.


Q: Can Remidon cause stomach upset or digestive issues?

A: Yes, official regulatory documents classify gastrointestinal issues among the common adverse reactions. These commonly reported issues include general stomach upset and nausea.


Q: Are headaches a common side effect reported with Remidon?

A: Headache is one of the primary symptoms the drug is used to treat, so it is not listed as a typical side effect. However, official labeling does contain a specific warning that frequent, prolonged use carries the risk of developing a condition known as Medication Overuse Headache (MOH).


Q: Does Remidon interact with over-the-counter pain relievers?

A: Official documentation strictly advises against using this medicine with any other products that contain Acetaminophen or Paracetamol. This caution is in place to prevent the risk of unintentional excessive intake of the total analgesic component.


Q: Is it safe to take Remidon with common dietary supplements?

A: Official drug labels list specific, known interactions with certain medications. Regarding supplements, regulatory bodies generally advise that users inform their healthcare provider about all vitamins, supplements, and herbal remedies they are taking, as some supplements may have the potential to alter how the body metabolizes or responds to the drug.


Q: Can Remidon be used by older adults?

A: The product is generally allowed for use in adults 12 years of age and older. However, regulatory documents often caution that older adults may be more sensitive to the effects of medications, particularly the CNS stimulant component (Caffeine). Careful consideration and monitoring are generally appropriate for this population.


Q: Is Remidon suitable for children or adolescents?

A: Official regulatory documents explicitly prohibit the use of this product in children under 12 years of age. For adolescents aged 12 years and older, the use is permitted according to adult dosage. Consultation with a healthcare provider is appropriate for establishing safe use.


Q: What happens if I miss a scheduled time to use Remidon?

A: Because this pain reliever is taken on an 'as-needed' basis, regulatory documents do not provide specific instructions for a missed dose. The primary instruction is to strictly ensure that the minimum required time interval elapses between any two doses and to avoid exceeding the maximum daily amount.


Q: Is it normal to feel tired when first starting Remidon?

A: The official list of common side effects is generally related to the Central Nervous System (CNS) stimulant, Caffeine, and includes nervousness, insomnia, and irritability. Tiredness or fatigue is not typically listed among the common side effects; the common effects are primarily related to CNS stimulation.


Q: Does Remidon carry a warning about potential long-term effects?

A: Yes, the official labeling includes warnings for two distinct long-term risks. It warns about the potential for severe liver damage associated with the cumulative intake of the Acetaminophen component, and it explicitly notes the risk of developing Medication Overuse Headache (MOH) associated with prolonged, frequent use.


Q: Can Remidon affect my ability to drive or operate machinery?

A: Official labeling advises caution regarding driving and operating machinery. Due to the potential for CNS-related side effects, such as nervousness or dizziness, users are generally advised to be fully aware of their reaction to the medication before engaging in activities that require full mental alertness.


Q: Is there a generic version of Remidon available?

A: The product contains two common, non-proprietary active ingredients, Acetaminophen and Caffeine. The regulatory approval system typically lists multiple manufacturers producing therapeutically equivalent, generic versions of this fixed-dose combination product.


Q: Is Remidon described as an 'addictive' substance?

A: For the non-opioid combination of Acetaminophen and Caffeine, it is not classified by regulatory bodies as a controlled or addictive substance. The dependence warnings that are sometimes associated with similar products apply only to those containing other, specific ingredients.


Q: Are there specific tests a doctor must do before prescribing Remidon?

A: Regulatory documents do not strictly mandate specific tests prior to use for the general population. However, for individuals with pre-existing hepatic impairment or those who consume alcohol regularly, consultation with a healthcare provider is appropriate. The provider may then determine if liver function monitoring is necessary.


Q: How is Remidon different from placebo in research studies?

A: Clinical trials reviewed by regulatory agencies demonstrated that the combination of Acetaminophen and Caffeine resulted in a change in pain and associated symptoms. The studies confirmed that this effect was statistically superior to that observed with a placebo.


Q: Is it possible for Remidon to stop working over time?

A: The regulatory information on frequent, prolonged use warns of the risk of developing Medication Overuse Headache (MOH). For acute pain treatments, this condition involves the pain relievers becoming ineffective or paradoxically leading to more frequent headaches over time.


Q: Are certain types of people more likely to experience side effects?

A: Yes. Official labeling highlights that the risk of severe adverse outcomes is heightened for certain populations. Specifically, the risk of hepatotoxicity (severe liver damage) is elevated in individuals with pre-existing hepatic impairment and those who regularly consume alcohol.


Q: What should I do if I have a skin rash after starting Remidon?

A: Regulatory warnings state that rare but severe skin reactions (such as SJS, TEN, and AGEP) may occur. Regulatory warnings advise that if a skin rash or any allergic reaction develops, the medicine should be discontinued, and medical attention should be sought promptly for evaluation.


Q: Does Remidon affect blood pressure readings?

A: The product contains Caffeine, a Central Nervous System (CNS) stimulant. Regulatory documents caution that the CNS stimulant component may be associated with cardiovascular effects. Therefore, the medicine should be used with caution in individuals with pre-existing high blood pressure or other cardiovascular conditions.


Q: Are there any specific mood changes associated with Remidon use?

A: Official regulatory documents list several psychiatric and nervous system disorders as common adverse reactions. These common changes include nervousness and irritability, which are typically linked to the presence of the stimulant component.


Q: Does Remidon interact with common cold or flu medicines?

A: Yes, interactions are possible. Regulatory agencies strictly advise against combining this medicine with other products containing Acetaminophen. Furthermore, because many cold and flu medicines contain CNS stimulants, official labeling also advises limiting the use of other Caffeine-containing products to mitigate additive CNS-related side effects.

How should Remidon be stored and disposed of?

Storage Requirements

Remidon must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), to preserve the stability of the active ingredients. The medication must be kept in its original container, tightly closed, and protected from excessive heat, light, and moisture; storage in areas like the bathroom should be avoided. A primary requirement is to store Remidon out of the sight and reach of children.

Disposal Instructions

Expired or unused Remidon should not be flushed down the toilet or thrown in the household trash unless directed by the package label. The recommended method for disposal is to use an official drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container before being placed in the trash, following local regulations for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Remidon found in:

A-Z Index: